ORAMED PHARMACEUTICALS INC. Business Combination, Acquisition Related Costs
ORAMED PHARMACEUTICALS INC. (ORMP) reported Business Combination, Acquisition Related Costs of $180.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2025-05-15
- ORAMED PHARMACEUTICALS INC. business combination, acquisition related costs for the quarter ending 2025-03-31 was $180.00K.
| Period end | Business Combination, Acquisition Related Costs 3 month |
|---|---|
| 2025-03-31 | $180.00K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |